Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis
September 25, 2024 08:00 ET
|
Palisade Bio, Inc.
– Completion of nonclinical safety and toxicity studies, Phase 1 clinical trial design and established Maximum Recommended Starting Dose – Completion of pre- Clinical Trial Application (CTA)...
U.S. IVD And LDT For Autoimmune Diseases Market Research 2024-2030: Rising Awareness of Autoimmune Disorders Fuels Demand for Innovative Diagnostic Solutions
September 24, 2024 10:29 ET
|
Research and Markets
Dublin, Sept. 24, 2024 (GLOBE NEWSWIRE) -- The "U.S. IVD And LDT For Autoimmune Diseases Market Size, Share & Trends Analysis Report By Type (IVD, LDT), By Technology (Immunoassays, Clinical...
Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis
August 08, 2024 08:00 ET
|
Palisade Bio, Inc.
– Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) on track to commence before year end – Based on the modeling and simulations, Palisade has established dose...
Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone
August 06, 2024 02:30 ET
|
Abivax
Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) surpassed the...
United Kingdom Ulcerative Colitis Market to Reach US$ 548.1 Million by 2031, Says CoherentMI
July 30, 2024 04:08 ET
|
CMI
Burlingame, July 30, 2024 (GLOBE NEWSWIRE) -- CoherentMI published a report, titled, United Kingdom Ulcerative Colitis Market was valued at US$ 421.3 Million in the year 2023 and is anticipated to...
Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event
July 18, 2024 08:00 ET
|
Biora Therapeutics, Inc.
Pharmacokinetic and tissue data confirm NaviCap platform delivers topically through the entire colon, with lower systemic concentrations, as desired.
Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
July 16, 2024 08:05 ET
|
Organovo, Inc.
Organovo presented on the Company’s near and long-term outlook, operational plans, at the Jones Trading Healthcare Conference in Encinitas, CA.
Global Gut Microbiota Markets, Insights and Forecasts to 2031 - Key Players Danone, IFF, Ferring, and Nestle Focusing on R&D and Strategic Partnerships
July 12, 2024 05:35 ET
|
Research and Markets
Dublin, July 12, 2024 (GLOBE NEWSWIRE) -- The "Gut Microbiota Market, By Product, By Application, By Disease Type, By End Users, By Distribution Channel: By Region - Market Size, Industry Dynamics,...
Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024
July 08, 2024 08:00 ET
|
Biora Therapeutics, Inc.
Event to highlight results from the clinical trial of BT-600, an orally administered drug-device combination in development for ulcerative colitis.
Biora Therapeutics Announces Positive Clinical Trial Results for BT-600
July 01, 2024 08:00 ET
|
Biora Therapeutics, Inc.
BT-600 was well tolerated and met all trial objectives, demonstrating the NaviCap platform’s ability to deliver therapeutics directly to the colon